This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Guided Therapeutics Reports Year End And Fourth Quarter 2012 Results

“As we ramp up our manufacturing, we are targeting 15 to 20 LuViva devices to the EU and other select markets in the second quarter and currently have commitments for the units along with a significant number of disposables. Our plan is to add distribution territories in conjunction with anticipated increases in our manufacturing capacity to carefully control the product roll out market to market.

“We also received notice of allowance of a European patent for LuViva in January,” Dr. Faupel added. “The patent covers the fundamental spectroscopy of the platform technology from which the LuViva and esophageal cancer detection products are derived. Additionally, we received notice that our clinical trial results for LuViva will be published, pending acceptance of minor revisions, in a major peer-reviewed gynecology journal later this year. We also received notification of regulatory approval in Singapore and plan to open that market and surrounding territories to sales later this year. We continue to await word from the FDA regarding LuViva, which is expected later in the spring.

“Work on our esophageal cancer program continues to move forward and in February we brought the worldwide rights to the technology back in house. We also received good news from the FDA that the esophageal product does not represent a significant risk to patients and therefore does not require an investigational device exemption in order to continue clinical trials later this year,” Dr. Faupel said.

Conference Call

Guided Therapeutics will hold a conference call at 11:00 a.m. EDT on Thursday, March 28, 2013, to discuss its financial results and corporate developments. Interested parties are invited to listen to the call live over the Internet at http://www.guidedinc.com/investors.htm or http://www.viavid.net. The live call is also available by dialing (888) 438-5535 or for international callers (719) 785-1765.

A replay of the teleconference will be available on http://www.guidedinc.com/investors.htm. A replay will also be available, until April 4, 2013, by dialing (877) 870-5176 or for international callers (858) 384-5517, and using pin number 7470435.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company’s first planned product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and subsequent quarterly reports.

GUIDED THERAPEUTICS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2012 AND 2011

(In Thousands, Except Per Share Data)
         

Three Months Ended

Twelve Months Ended

December 31

December 31
 
In Thousands except per share data 2012 2011 2012 2011
Service Revenue $ 1,012 $ 896 $ 3,338 $ 3,597
 
Sales Revenue - 25 72 25
Cost of goods sold   -     106     117     106  
Gross loss   -     (81 )   (45 )   (81 )
Cost and Expenses
Claim Settlement - 1,337 - 3,622
Research & Development 830 755 3,227 2,779
Sales and Marketing 153 87 424 287
General & Administration   1,196     1,518     3,923     3,584  
Total Operating Expense   2,179     3,697     7,547     10,272  
 
Operating Loss (1,167 )

(2,882

)
(4,281 ) (6,756 )
 
Interest & Other Income (expense)   (20 )   121     (72 )   112  
 
Net Loss (1,187 )

(2,761

)
(4,353 ) (6,644 )
       
Net Loss Attributable to Common Stockholders $ (1,187 ) $ (2,761 ) $ (4,353 ) $ (6,644 )
 
Basic and Diluted Net Loss per Share $ (0.02 ) $ (0.05 ) $ (0.08 ) $ (0.14 )
 
Basic and Diluted

Weighted Average Shares Outstanding
  62,250     50,317   57,429     48,868  
 

Selected Balance Sheet Data (Unaudited)

(In Thousands)
             
December 31, 2012 December 31, 2011
Cash & Cash Equivalents $ 1,044 $ 2,200
Working Capital (472 ) 162
Total Assets 3,478 4,310
Accumulated Deficit (92,098 ) (85,089 )
Stockholders’ Equity 1,133 1,473

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,568.53 -127.94 -0.73%
S&P 500 2,079.65 -12.01 -0.58%
NASDAQ 5,088.63 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs